Charles River Laboratories International reported first-quarter revenue of $995.83 million, surpassing Wall Street estimates but highlighting ongoing financial difficulties, including a year-over-year organic revenue decline of 1.5%. The adjusted earnings per share (EPS) fell 12% to $2.06, with management maintaining a cautious outlook for 2026, forecasting further revenue drops. Despite a recent $200 million stock buyback and a positive one-year return, the company faces significant long-term concerns following a 43.4% decline over five years.
Loading timeline…